← FDA DRUG APPROVALS

FDA ANDA · ANDA076092

KETAMINE HYDROCHLORIDE

Sponsor: EUGIA PHARMA

APPLICATION
ANDA076092
TYPE
ANDA
ORIGINAL APPROVAL
2001-12-28
LATEST ACTION
2023-06-23
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

KETAMINE HYDROCHLORIDEPrescription
KETAMINE HYDROCHLORIDE EQ 50MG BASE/ML · INJECTABLE · INJECTION
KETAMINE HYDROCHLORIDEPrescription
KETAMINE HYDROCHLORIDE EQ 100MG BASE/ML · INJECTABLE · INJECTION
KETAMINE HYDROCHLORIDEPrescription
KETAMINE HYDROCHLORIDE EQ 10MG BASE/ML · INJECTABLE · INJECTION

Approval history

2023-06-23Labeling · Supplement 29 · standardAP
2018-12-31Labeling · Supplement 23 · standardAP
2012-10-05Labeling · Supplement 18 · standardAP
2008-09-30Labeling · Supplement 9AP
2002-10-25Manufacturing (CMC) · Supplement 1AP
2002-10-25Labeling · Supplement 2AP
2001-12-28OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →